Patients with atrial fibrillation (AF) are at an increased risk for thrombosis, and anticoagulant
therapy, preferably with a direct oral anticoagulant (DOAC) for most patients, is indicated for …

Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia and is associated
with an increased risk of cardioembolic stroke. Oral anticoagulation reduces the risk of …

Anticoagulation is the mainstay for stroke prevention in patients with atrial fibrillation (AF).
Many patients with AF also have a concomitant indication for either single or dual …

Based on recent studies, we want to provoke thoughts on how to further optimize research
on antiplatelet treatment in patients on oral anticoagulation (OAC). One in three patients …

In patients with AF, adjusted-dose warfarin and antiplatelet agents reduce the risk for stroke
by≈ 65% and by≈ 20%, respectively. 17 However, oral antiplatelet agents do not perform …

Approximately, 1 in 5 patients with atrial fibrillation (AF) will undergo percutaneous coronary
intervention (PCI) or experience an acute coronary syndrome (ACS). In light of their …

For secondary prevention of coronary artery disease (CAD), oral antiplatelet therapy is
essential. In case of coronary intervention, temporary dual antiplatelet therapy is mandatory …

Chronic oral anticoagulation (OAC) treatment is mandatory in patients with mechanical heart
valves, the majority of the patients with atrial fibrillation (AF), patients with deep venous …

Abstract Purpose of Review Coronary heart disease (CHD) and atrial fibrillation (AF) are
among the most common cardiovascular diseases. A significant proportion of patients have …

Background We studied the concomitant use of single antiplatelet therapy (SAPT) on the
efficacy and safety of the anti‐Xa agent edoxaban in patients with atrial fibrillation (AF) …